Novo Nordisk's Tresiba impresses in comparative study

12 November 2016
novo-nordisk-large

Results from a comparative pharmacodynamics study have shown the potential benefits of Tresiba (insulin degludec) over a rival in patients with type 1 diabetes.

Danish diabetes giant Novo Nordisk (NOV: N), which gained US approval to sell Tresiba in September 2015, presented the results at the 16th Annual Diabetes Technology Meeting in Bethesda, USA.

Tresiba (0.4 U/kg) was compared with insulin glargine U300 and resulted in lower day-to-day and within-day variability in glucose-lowering effect than its competitor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical